The US regulator has asked for a second phase 3 study on Santhera’s Duchenne muscular dystrophy (DMD) drug Raxone (idebenone), delaying possible approval by several years and sending the Swiss ...

Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after getting confirmation it will be covered by the NHS in all four nations.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

The company’s upcoming pivotal safety trial for LYN-005 is scheduled to begin in the first half of 2025. Credit: PeopleImages.com – Yuri A/Shutterstock. Lyndra Therapeutics has announced the immediate ...

HITC Healthcare Integrated Technologies, Inc.

At close: 29 January at 17:30:32 CET ...